TIDMFUM
RNS Number : 6508V
Futura Medical PLC
06 April 2023
6 April 2023
Futura Medical plc
("Futura" or the "Company")
Directors' / PDMR Dealing and Grant of Options
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology currently focused on sexual health and pain,
today announces that it has today, granted options over a total of
1,934,000 ordinary shares of 0.2p each in the Company ("Ordinary
Shares") to employees and Directors, of which 858,000 options were
granted to Directors and PDMRs as detailed below. The options are
part of annual awards made by Futura in accordance with existing
share schemes.
Total number
Number of options Total number
of options Exercise held following of Ordinary
Director granted price Exercise period notification Shares held
----------- ----------- -------- ----------------- --------------- ------------
1 April 2026 - 31
J H Barder 330,000 43.60p Mar 2033 2,415,716 1,440,972
1 April 2026 - 31
A Hildreth 264,000 43.60p Mar 2033 1,772,340 142,857
1 April 2026 - 31
K W James 264,000 43.60p Mar 2033 1,945,227 299,581
Of the total 1,934,000 options, 1,046,000 were granted under the
Futura Medical plc Enterprise Management Incentive Scheme, and
888,000 were granted under the unapproved scheme.
Vesting is subject to the achievement of a performance-related
milestone and that the Director/PDMR/employee remains employed with
the Company as at the date of exercise. Further disclosures are
contained in the tables below.
S
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction ("ED") through a unique
evaporative mode of action. Futura has previously conducted an
initial Phase 3 study using MED3000 in ED, referred to as "FM57"
which enabled Futura to be granted a CE Mark in 2021. A second
confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED
patients and endpoints at 24 weeks, demonstrating that MED3000
presents an effective clinically proven treatment for ED with a
rapid speed of onset and a favourable benefit versus risk profile
ideally suited for OTC classification.
Eroxon(R) is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile
dysfunction under the brand Eroxon(R) with a key claim of "Helps
you get an erection within 10 minutes". Eroxon(R) is the agreed
brand name in certain regions such as the EU whereas MED3000
continues to be the internal code name used by the Company and also
in reference to countries where regulatory approval or commercial
distribution agreements have not yet been achieved.
www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name James Barder
------------------------------- --------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- --------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------- --------------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of the Options over Ordinary Shares of 0.2
financial instrument, pence each
type of instrument
Identification code GB0033278473
------------------------------- --------------------------------------
b) Nature of the transaction Grant of options over Ordinary Shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
- 330,000
----------
------------------------------- --------------------------------------
d) Aggregated information N/A single transaction
- Aggregated volume
- Price
------------------------------- --------------------------------------
e) Date of the transaction 6 April 2023
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Angela Hildreth
------------------------------- ------------------------------------------
Reason for the notification
2
---------------------------------------------------------------------------
a) Position/status Finance Director and
Chief Operating Officer
------------------------------- ------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------- ------------------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------- ------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Options over Ordinary Shares of 0.2 pence
financial instrument, each
type of instrument
Identification code GB0033278473
------------------------------- ------------------------------------------
b) Nature of the transaction Grant of options over Ordinary Shares
------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
- 264,000
----------
------------------------------- ------------------------------------------
d) Aggregated information N/A single transaction
- Aggregated volume
- Price
------------------------------- ------------------------------------------
e) Date of the transaction 6 April 2023
------------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- ------------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Ken James
------------------------------- ------------------------------------------
Reason for the notification
2
---------------------------------------------------------------------------
a) Position/status Executive Director
and Head of R&D
------------------------------- ------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Futura Medical plc
------------------------------- ------------------------------------------
b) LEI 21380053QLT46UNV2303
------------------------------- ------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Options over Ordinary Shares of 0.2 pence
financial instrument, each
type of instrument
Identification code GB0033278473
------------------------------- ------------------------------------------
b) Nature of the transaction Grant of options over Ordinary Shares
------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
- 264,000
----------
------------------------------- ------------------------------------------
d) Aggregated information N/A single transaction
- Aggregated volume
- Price
------------------------------- ------------------------------------------
e) Date of the transaction 6 April 2023
------------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- ------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFIISFIRIIV
(END) Dow Jones Newswires
April 06, 2023 06:03 ET (10:03 GMT)
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
